TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06219876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser treatment
Description: The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity laser treatment
Description: The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wrist splint
Description: wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
Study: NCT06371989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image guided vacuum assisted biopsy
Description: Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
Study: NCT05433064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulator
Description: Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
Study: NCT00479128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
Study: NCT02966665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123, MitoQ, BH4
Description: Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
Study: NCT01858285

Intervention type: GENETIC
Intervention: Exome and/or whole genome sequencing
Study: NCT03459534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib HCl
Description: 1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature.
Study: NCT04008303

Intervention type: PROCEDURE
Intervention: Migraine surgery
Description: Surgical decompression of neuromuscular structures causing migraine headaches.
Study: NCT01465867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill Placebo
Description: Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selenium + L-Thyroxine (LT4)
Description: 83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Pill Placebo + L-Thyroxine (LT4)
Description: Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)
Study: NCT01713582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
Study: NCT01651676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VQ11 validation
Description: Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug.
Study: NCT01713582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
Study: NCT02797301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synthetic test
Description: The children performed the synthetic test with no time restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synthetic test
Description: The children performed the synthetic test with no time restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerised test
Description: The children performed the computerised test with no time restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerised test
Description: The children performed the computerised test with no time restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerised test
Description: The children performed the computerised test with no time restriction.
Study: NCT03581149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate/Magnesium Citrate Laxative
Description: ● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L polyethylene glycol/ascorbic acid
Description: * First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
Study: NCT02951403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elbow arthroscopy
Description: Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative treatment
Description: Physiotherapy protocol is introduced to patients.
Study: NCT04089670

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Acceptance and Commitment Therapy Intervention
Description: The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week.
Study: NCT00705913

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
Description: Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carpentier-Edwards Magna Tissue Valve
Description: Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
Study: NCT04552041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospekta
Description: Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study: NCT04416165

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
Study: NCT01550029

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling/Healthy Lifestyle
Description: A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle.
Study: NCT02980991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
Study: NCT04245306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized test for pragmatic inferences
Description: Computerized tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized test for pragmatic inferences
Description: Computerized tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computerized test for pragmatic inferences
Description: Computerized tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized test for pragmatic inferences
Description: Computerized tests
Study: NCT04738240

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intra-operative endoscopy
Description: Intra-operative endoscopy to assess rectal anastomosis
Study: NCT04551898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP593
Description: Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP593
Description: Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP593
Description: Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match BGB-DXP593 administered as specified in the treatment arm
Study: NCT01393483

Intervention type: OTHER
Intervention: serum and tissue mesothelin
Description: Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs.

Intervention type: OTHER
Intervention: serum and tissue mesothelin
Description: Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.

Intervention type: OTHER
Intervention: serum and tissue mesothelin
Description: Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
Study: NCT03735017

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Interactive Virtual Reality Walking
Description: Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Reality Walking
Description: Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study: NCT03237390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT03537001

Intervention type: OTHER
Intervention: Penthrox
Description: Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
Study: NCT01332851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR)
Description: PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource and Referral
Description: Needs assessment, followed with a resource packet sent by mail
Study: NCT01858285

Intervention type: GENETIC
Intervention: Exome and/or whole genome sequencing

Intervention type: GENETIC
Intervention: Exome and/or whole genome sequencing
Study: NCT04119063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: powered orthosis
Description: Novel powered leg brace to provide assistance during walking.
Study: NCT03877016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
Study: NCT01728974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharyngeal topical anesthesia
Description: Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
Study: NCT01605409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency cardiopulmonary bypass under ongoing CPR
Description: Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard ACLS
Description: Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACLS
Description: Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible.
Study: NCT00667940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rater training workshop
Description: Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
Study: NCT03427814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60 mg orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 mg orally twice daily
Study: NCT03978598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel
Description: Immediate v. Standard insertion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel
Description: Immediate v. Standard insertion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexplanon
Description: Implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexplanon
Description: Implant.